Cost-effectiveness of a cardiovascular polypill strategy (aspirin, atorvastatin, ramipril) for the secondary prevention of cardiovascular disease based on real life improvement in risk factor control
15 April 2021 (00:00 - 00:00)
Organised by:
About the speaker
Ferrer Internacional, Barcelona (Spain)
4 More presentations in this session
Mr G. Kleinnibbelink (Nijmegen, NL)
Ms A. Abdul Razzack (Hyderabad, IN)
Access the full session
The Event
ESC Preventive Cardiology 2021
15 April - 17 April 2021
You may be interested in
Congress Presentation
